ProQR Therapeutics (PRQR) Net Cash Flow (2013 - 2026)
ProQR Therapeutics (PRQR) posted Net Cash Flow of -$14.0 million for Q1 2026, up 26.27% sequentially from -$18.9 million in Q4 2025, and up 22.33% YoY from -$11.4 million in Q1 2025.
ProQR Therapeutics (PRQR) Net Cash Flow (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Net Cash Flow for 14 years, with the latest figure at -$14.0 million in Q1 2026.
- Quarterly Net Cash Flow rose 22.33% year-over-year to -$14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.9 million (down 234.11% YoY) and the FY2025 annual result came in at -$66.9 million, down 330.63% from the prior year.
- Net Cash Flow rose to -$14.0 million in Q1 2026 per PRQR's latest filing, from -$18.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $60.5 million in Q4 2024 and troughed at -$59.9 million in Q3 2022.
- A 5-year average of -$7.7 million and a median of -$14.0 million in 2026 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow sank 431.09% in 2022, then jumped 16634.98% in 2024.
- Over 5 years, Net Cash Flow stood at -$4.1 million in 2022, then soared by 108.75% to $361515.8 in 2023, then surged by 16634.98% to $60.5 million in 2024, then tumbled by 131.32% to -$18.9 million in 2025, then grew by 26.27% to -$14.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$14.0 million, -$18.9 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -13.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.97 Mn |
| Mar 31, 2026 | -13.97 Mn |
| Dec 31, 2025 | -18.95 Mn |
| Dec 31, 2025 | -18.95 Mn |
| Sep 30, 2025 | -15.02 Mn |
| Sep 30, 2025 | -15.02 Mn |
| Jun 30, 2025 | -13.97 Mn |
| Jun 30, 2025 | -13.97 Mn |
| Mar 31, 2025 | -17.99 Mn |
| Mar 31, 2025 | -17.99 Mn |
| Dec 31, 2024 | 60.50 Mn |
| Dec 31, 2024 | 60.50 Mn |
| Sep 30, 2024 | 11.65 Mn |
| Sep 30, 2024 | 11.65 Mn |
| Jun 30, 2024 | -7.99 Mn |
| Jun 30, 2024 | -7.99 Mn |
| Mar 31, 2024 | -36.16 Mn |
| Mar 31, 2024 | -36.16 Mn |
| Dec 31, 2023 | 361,515.81 |
| Dec 31, 2023 | 361,515.81 |